Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.31 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.31 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.31 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62903 | 0.85 | MTNR1A (0.33) | — | |
| SCHEMBL6886568 | 0.82 | AOC3 (0.34) | AOC3ALDH1A1CYP3A4 | |
| SCHEMBL4060952 | 0.81 | TAAR1 (0.33) | AOC3ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL7462090 | 0.80 | CYP3A4 (0.33) | AOC3ALDH1A1CYP3A4 | |
| SCHEMBL8925096 | 0.77 | ABCG2 (0.38) | ABCG2ALDH1A1 | |
| SCHEMBL83574 | 0.75 | NQO2 (0.40) | AOC3ABCG2ALDH1A1CYP3A4NQO2 | |
| SCHEMBL5907509 | 0.74 | NQO2 (0.37) | AOC3ABCG2ALDH1A1CYP3A4NQO2 | |
| SCHEMBL161183 | 0.74 | ABCG2 (0.39) | AOC3ABCG2ALDH1A1CYP3A4NQO2 | |
| SCHEMBL8939774 | 0.73 | MAOB (0.43) | — | |
| SCHEMBL3404505 | 0.72 | ABCG2 (0.37) | AOC3ABCG2ALDH1A1CYP3A4NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | claimed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | claimed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | claimed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | claimed |
| EP-2392561-A1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2011-12-07 | — | — | EP | claimed |
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | RHEOGENE, INC. | 2009-04-30 | — | — | US | claimed |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-29 | — | — | US | claimed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| EP-1534658-A4 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1534658-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | claimed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | claimed |
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1534658-A4 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1534658-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | ESRRB, ESRRA, KDELR1 | AOC3 3690/4885ABCG2 4864/4885ALDH1A1 3260/4885 |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | AOC3 3690/4885ABCG2 4864/4885ALDH1A1 3260/4885 |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | AOC3 3690/4885ABCG2 4864/4885ALDH1A1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.